A 2006 study identified mutations in KEAP1 in non-small cell lung cancer (NSCLC), leading to sustained elevated levels of NRF2, and first proposed that NRF2 might contribute to cancer progression and chemotherapy resistance. This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.